Damora Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Damora Therapeutics Inc.
- Former names
- Galecto, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Waltham
- Headquarters state / province
- Massachusetts
- Headquarters country
- Denmark
- Fiscal year end
- December
- Ticker symbol
- DMRA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001800315
- EIN
- 37-1957007
Board of directors
-
Amit Munshi · DirectorSince 2023
-
Amy B. Wechsler · DirectorSince 2024
-
Andrew Cheng · DirectorSince 2026
-
Anne Prener · DirectorSince 2023
-
Cameron Turtle · DirectorSince 2026
-
Carl Goldfischer · DirectorSince 2023
-
Chau Quang Khuong · DirectorSince 2023
-
Christopher W. Cain · DirectorSince 2025
-
David Shapiro · DirectorSince 2023
-
Hans T. Schambye · Director · Chief Executive OfficerSince 2023
-
Jayson Donald Alexander Dallas · DirectorSince 2023
- Since 2026
-
Julianne Bruno · DirectorSince 2025
-
Michael Landsittel · DirectorSince 2026
- Since 2025
Chief executives
Hans T. Schambye
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of April 28, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
99.9%
Board connections
10 of this board's directors also sit on 21 other boards.
- via Christopher W. Cain and Peter Evan Harwin
- via Christopher W. Cain and Peter Evan Harwin
- via Cameron Turtle and Peter Evan Harwin
- via Cameron Turtle and Peter Evan Harwin
- via Christopher W. Cain and Peter Evan Harwin
- via Amit Munshi and Jennifer Jarrett
- via Jennifer Jarrett
- via Amit Munshi
- via Amy B. Wechsler
- via Peter Evan Harwin
- via David Shapiro
- via Peter Evan Harwin
- via Amit Munshi
- via Anne Prener
- via Peter Evan Harwin
- via Chau Quang Khuong
- via Jennifer Jarrett
- via Jennifer Jarrett
- via Andrew Cheng
- via Andrew Cheng
- via Peter Evan Harwin
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $30,653
- 4 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 6, 2026 | Winslow Garrett Officer (General Counsel) | Open-market sale | −245 | $29.98 | $7,345 |
| Jul 3, 2026 | Winslow Garrett Officer (General Counsel) | Option exercise | +680 | — | — |
| Mar 30, 2026 | Jennifer Jarrett Director, Officer (See Remarks) | Grant or award | +500,000 | — | — |
| Feb 9, 2026 | Julianne Bruno Director | Option exercise | +129,000 | — | — |
| Feb 9, 2026 | Peter Evan Harwin Director, 10% owner | Option exercise | +5,809,000 | — | — |
| Feb 9, 2026 | Peter Evan Harwin Director, 10% owner | Option exercise | +2,904,000 | — | — |
| Jan 5, 2026 | Sattarzadeh Sherwin Officer (Chief Operating Officer) | Grant or award | +190,376 | — | — |
| Jan 5, 2026 | Hewes L. Becker Officer (Chief Medical Officer) | Grant or award | +264,629 | — | — |
| Jan 2, 2026 | Hans T. Schambye Director, Officer (Chief Executive Officer) | Option exercise | +1,360 | — | — |
| Jan 2, 2026 | Winslow Garrett Officer (General Counsel) | Option exercise | +680 | — | — |
| Jan 2, 2026 | Firmani Lori Officer (Chief Financial Officer) | Option exercise | +374 | — | — |
| Jan 2, 2026 | Hans T. Schambye Director, Officer (Chief Executive Officer) | Open-market sale | −700 | $21.38 | $14,966 |
| Jan 2, 2026 | Winslow Garrett Officer (General Counsel) | Open-market sale | −255 | $21.38 | $5,452 |
| Jan 2, 2026 | Firmani Lori Officer (Chief Financial Officer) | Open-market sale | −135 | $21.41 | $2,890 |
| Jul 3, 2025 | Hans T. Schambye Director, Officer (Chief Executive Officer) | Option exercise | +1,360 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.